Health economic and outcomes research datasets have rarely been integral to product development and communication plans.
Recent polls paint a mixed picture of physicians' willingness to see pharma sales reps. What gives? Are no-see docs up or down, and what's behind the dissonant findings?
Now that payers are locking in discounts at launch from drugmakers, where do co-pay cards fit in the marketing mix?
The idea that 30 days is enough time for the FDA to evaluate anything is, of course, quite silly. But Sen. Cruz takes it one step further.
Here are some compelling campaigns that invoke a visceral response—you laugh, cry, even cringe—followed by a more thoughtful and inspired reaction to learn more.
We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.
DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.
Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.
The traditional line of attack is genuine and requires little in the way of spin—yet still, every time a Turing rears its head, it gets blown back in small and indigestible pieces.
The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.
- Five things for pharma marketers to know: Friday, February 5, 2016
- Why Gathering Health Economic Data for Cancer Drugs is Now Essential
- Ascension Health ups Ragone to chief marcomms officer
- House Oversight committee upbraids Turing, Valeant execs
- Burcin departs Havas network for Klick Health in senior-staffing push